Today: 8 June 2026
Browse Category

NASDAQ:AMGN 22 December 2025 - 30 March 2026

SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

Schwab’s U.S. Dividend Equity ETF (SCHD) increased health care holdings to 18.5% in its annual rebalance, adding Abbott Laboratories and UnitedHealth Group near the top at about 3.8% each. SCHD attracted $4 billion in Q1 as U.S. dividend funds pulled in $24.1 billion, the highest first-quarter inflow in four years. SCHD closed at $30.48 Monday, up 0.13%.
30 March 2026
············
Dow Jones futures tick up as Wall Street braces for retail sales, jobs and CPI

Dow Jones futures tick up as Wall Street braces for retail sales, jobs and CPI

Dow futures rose 45 points to 50,264 early Tuesday after the index closed at a record 50,135.87 on Monday. Investors await U.S. retail sales data at 8:30 a.m. ET, with forecasts at 0.4%, followed by key payroll and inflation reports later this week. Tech stocks led Monday’s rebound, while losses in Amgen and Merck weighed on the Dow. Earnings from major consumer and industrial firms are also due.
10 February 2026
··
Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen shares dropped 1.8% to $377.28 in mid-afternoon trading Monday, weighing on the Dow Jones Industrial Average. The decline followed news of an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% fall in Enbrel sales last quarter. Broader drug stocks lagged while traders awaited key U.S. jobs and inflation data later in the week.
9 February 2026
····
Dow Jones Industrial Average slips under 50,000 as AI shakeout bites; payrolls, CPI loom

Dow Jones Industrial Average slips under 50,000 as AI shakeout bites; payrolls, CPI loom

The Dow Jones fell 133 points to 49,983 in Monday morning trade, slipping below 50,000 after Friday’s record close. The S&P 500 dipped 0.08% and the Nasdaq was flat as investors rotated out of tech and into industrial and defensive stocks. Amgen and Merck together shaved about 79 points from the Dow. Traders await key payrolls and inflation data later this week.
9 February 2026
···
Amgen stock jumps to a 52-week high; here’s what to watch before Monday’s open

Amgen stock jumps to a 52-week high; here’s what to watch before Monday’s open

Amgen shares jumped 4.49% to $384.32 Friday, hitting a 52-week high as the Dow closed above 50,000 for the first time. The move followed strong quarterly results and a $2.52 per share dividend declaration. CVS Caremark will drop Amgen’s Prolia from some preferred lists in April, citing biosimilar competition. Investors await next week’s delayed U.S. jobs and inflation data.
8 February 2026
·
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen shares fell 0.7% to $344.75 Friday, ending a six-day winning streak after reaching a 52-week high of $349.98 on Thursday. The stock remains up about 4% for the week. Investors are awaiting the Feb. 3 earnings call for updates on Amgen’s obesity drug pipeline and guidance. The board approved a $2.52 quarterly dividend, payable March 6 to shareholders of record by Feb. 13.
24 January 2026
·
Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen shares fell 1.21% to $326.10 Friday, marking a second straight day of losses as the S&P 500 rose. Trading volume reached about 3.7 million shares. Truist maintained a “hold” rating and slightly raised its price target. Investors are watching next week’s J.P. Morgan Healthcare Conference and Amgen’s Feb. 3 earnings report.
10 January 2026
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

The FDA approved new denosumab biosimilars referencing Amgen’s Prolia and XGEVA after markets closed Monday. Amgen shares ended the day up 1.2% at $331.39. Fitch upgraded Amgen’s credit rating to BBB+ with a stable outlook. Post-market trading showed little immediate reaction.
23 December 2025
···
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen shares rose to around $331 on December 22, 2025, after the White House announced drug-pricing deals with major drugmakers, including Amgen. The company will offer Aimovig and Amjevita at $299 per month through direct-to-patient sales. Analysts said the agreements may ease tariff and political risks but are unlikely to significantly affect pharma profits in the near term.
22 December 2025
··
1 2

Stock Market Today

  • RTX Corp Price Targets Diverge as Analysts Weigh Growth and Risks
    June 8, 2026, 1:10 AM EDT. RTX Corp (NYSE: RTX) faces mixed analyst price target revisions amid split investment views. Jefferies raised its price target to $220, citing expected 7% annual organic sales growth through 2028 and stronger earnings per share (EPS) forecasts. Melius Research also upgraded the stock. Conversely, UBS, Morgan Stanley, Citi, and Erste Group trimmed targets or downgraded coverage, reflecting caution amid tariff challenges and geopolitical uncertainties. RTX reported a 21% rise in first-quarter 2026 adjusted EPS at $1.78 and raised its full-year EPS guidance amid $22.08 billion revenue. Raytheon secured key defense contracts, while Collins Aerospace and Pratt & Whitney expanded production capacities in Poland. Despite a stable fair value estimate at $215.27, investors remain watchful of tariff exposure, jet engine costs, and defense demand shifts impacting valuation.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop